Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of mirikizumab (LY3074828) in adults with moderate to severe plaque psoriasis has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2020-06-18